anti-HIgG(Fc)Fab-N-AAMT ADC (CAT#: ADC-AA-016)

A: This ADC product is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated through a noncleavable linker to Alfa-amanitin. Alfa-amanitin is a cytotoxic small molecule that inhibits RNA polymerase II, thereby halting RNA synthesis and causing RNA damage in targeted cells.

A: This ADC is designed for targeted therapy research, particularly in the context of cancers or diseases where the target cells express specific Fc receptors. It serves as a tool for pre-screening human monoclonal antibodies as potential ADC therapies, providing a more efficient and economical approach in early-stage drug development.

A: The ADC can be employed to screen and evaluate the efficacy of novel monoclonal antibodies by observing their ability to bind to the Fc fragment and mediate the targeted delivery of Alfa-amanitin to cancer cells. Successful binding and subsequent cell death can indicate the potential effectiveness of the monoclonal antibodies as ADC candidates.

A: The ADC can be tested in vitro using cancer cell lines that express Fc receptors, as well as in vivo models such as mouse xenografts of human tumors. These models help in studying the ADC's targeting capabilities, therapeutic efficacy, and potential side effects.

A: Internalization can be quantified using techniques such as flow cytometry, confocal microscopy, or live-cell imaging. These methods allow researchers to track the ADC's uptake by target cells and assess its intracellular localization and distribution over time.